{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T14:52:57Z","timestamp":1794495177827,"version":"4.9.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2016,5,28]],"date-time":"2016-05-28T00:00:00Z","timestamp":1464393600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100009139","name":"German Center for Infection Research","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100009139","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1007\/s40262-016-0416-1","type":"journal-article","created":{"date-parts":[[2016,5,28]],"date-time":"2016-05-28T06:50:02Z","timestamp":1464418202000},"page":"1535-1545","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":62,"title":["Dose-Dependent Bioavailability and CYP3A Inhibition Contribute to Non-Linear Pharmacokinetics of Voriconazole"],"prefix":"10.1007","volume":"55","author":[{"given":"Nicolas","family":"Hohmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"Kocheise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Carls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Burhenne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter E.","family":"Haefeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd","family":"Mikus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,5,28]]},"reference":[{"issue":"5","key":"416_CR1","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1124\/dmd.105.008672","volume":"34","author":"MF Paine","year":"2006","unstructured":"Paine MF, Hart HL, Ludington SS, Haining RL, Rettie AE, Zeldin DC. The human intestinal cytochrome P450 \u201cpie\u201d. Drug Metab Dispos. 2006;34(5):880\u20136.","journal-title":"Drug Metab Dispos"},{"key":"416_CR2","volume-title":"Clinical pharmacokinetics and pharmacodynamics","author":"M Rowland","year":"2011","unstructured":"Rowland M, Tozer TN. Clinical pharmacokinetics and pharmacodynamics. 4th ed. Baltimore: Lippincott Williams & Wilkins; 2011.","edition":"4"},{"issue":"6","key":"416_CR3","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1124\/dmd.107.019646","volume":"36","author":"SB Yanni","year":"2008","unstructured":"Yanni SB, Annaert PP, Augustijns P, Bridges A, Gao Y, Benjamin DK Jr, et al. Role of flavin-containing monooxygenase in oxidative metabolism of voriconazole by human liver microsomes. Drug Metab Dispos. 2008;36(6):1119\u201325.","journal-title":"Drug Metab Dispos"},{"key":"416_CR4","unstructured":"US Department of Health and Human Services, Center for Drug Evaluation and Research (CDER). Voriconazole clinical pharmacology biopharmaceutics review(s). 2002. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2002\/21-266_VFEND_biopharmr.pdf . Accessed 7 May 2015."},{"issue":"6","key":"416_CR5","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1124\/dmd.31.6.731","volume":"31","author":"SJ Roffey","year":"2003","unstructured":"Roffey SJ, Cole S, Comby P, Gibson D, Jezequel SG, Nedderman AN, et al. The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human. Drug Metab Dispos. 2003;31(6):731\u201341.","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"416_CR6","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.clpt.2006.04.004","volume":"80","author":"G Mikus","year":"2006","unstructured":"Mikus G, Schowel V, Drzewinska M, Rengelshausen J, Ding R, Riedel KD, et al. Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir. Clin Pharmacol Ther. 2006;80(2):126\u201335.","journal-title":"Clin Pharmacol Ther"},{"key":"416_CR7","unstructured":"Pfizer. Vfend\u00ae drug label. 2 May 2015. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/021266s038,021267s047,021630s028lbl.pdf .\u00a0Assessed 24 May 2016."},{"issue":"2","key":"416_CR8","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1128\/AAC.01123-08","volume":"53","author":"S Jeong","year":"2009","unstructured":"Jeong S, Nguyen PD, Desta Z. Comprehensive in vitro analysis of voriconazole inhibition of eight cytochrome P450 (CYP) enzymes: major effect on CYPs 2B6, 2C9, 2C19, and 3A. Antimicrob Agents Chemother. 2009;53(2):541\u201351.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"416_CR9","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.clpt.2005.12.305","volume":"79","author":"TI Saari","year":"2006","unstructured":"Saari TI, Laine K, Leino K, Valtonen M, Neuvonen PJ, Olkkola KT. Effect of voriconazole on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Clin Pharmacol Ther. 2006;79(4):362\u201370.","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"416_CR10","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1111\/j.1365-2125.2009.03534.x","volume":"68","author":"I Scholz","year":"2009","unstructured":"Scholz I, Oberwittler H, Riedel KD, Burhenne J, Weiss J, Haefeli WE, et al. Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype. Br J Clin Pharmacol. 2009;68(6):906\u201315.","journal-title":"Br J Clin Pharmacol"},{"issue":"10","key":"416_CR11","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1007\/s00228-013-1530-8","volume":"69","author":"C Eichbaum","year":"2013","unstructured":"Eichbaum C, Cortese M, Blank A, Burhenne J, Mikus G. Concentration effect relationship of CYP3A inhibition by ritonavir in humans. Eur J Clin Pharmacol. 2013;69(10):1795\u2013800.","journal-title":"Eur J Clin Pharmacol"},{"issue":"7","key":"416_CR12","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1007\/s00216-011-5675-y","volume":"402","author":"J Burhenne","year":"2012","unstructured":"Burhenne J, Halama B, Maurer M, Riedel KD, Hohmann N, Mikus G, et al. Quantification of femtomolar concentrations of the CYP3A substrate midazolam and its main metabolite 1\u2032-hydroxymidazolam in human plasma using ultra performance liquid chromatography coupled to tandem mass spectrometry. Anal Bioanal Chem. 2012;402(7):2439\u201350.","journal-title":"Anal Bioanal Chem"},{"issue":"10","key":"416_CR13","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1007\/s00228-013-1529-1","volume":"69","author":"C Markert","year":"2013","unstructured":"Markert C, Hellwig R, Burhenne J, Hoffmann MM, Weiss J, Mikus G, et al. Interaction of ambrisentan with clarithromycin and its modulation by polymorphic SLCO1B1. Eur J Clin Pharmacol. 2013;69(10):1785\u201393.","journal-title":"Eur J Clin Pharmacol"},{"issue":"5","key":"416_CR14","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/clpt.2011.164","volume":"90","author":"S Katzenmaier","year":"2011","unstructured":"Katzenmaier S, Markert C, Riedel KD, Burhenne J, Haefeli WE, Mikus G. Determining the time course of CYP3A inhibition by potent reversible and irreversible CYP3A inhibitors using a limited sampling strategy. Clin Pharmacol Ther. 2011;90(5):666\u201373.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"416_CR15","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/FTD.0b013e31820530cd","volume":"33","author":"A Hassan","year":"2011","unstructured":"Hassan A, Burhenne J, Riedel KD, Weiss J, Mikus G, Haefeli WE, et al. Modulators of very low voriconazole concentrations in routine therapeutic drug monitoring. Ther Drug Monit. 2011;33(1):86\u201393.","journal-title":"Ther Drug Monit"},{"issue":"6","key":"416_CR16","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/clpt.2013.27","volume":"93","author":"B Halama","year":"2013","unstructured":"Halama B, Hohmann N, Burhenne J, Weiss J, Mikus G, Haefeli WE. A nanogram dose of the CYP3A probe substrate midazolam to evaluate drug interactions. Clin Pharmacol Ther. 2013;93(6):564\u201371.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"416_CR17","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/bcp.12502","volume":"79","author":"N Hohmann","year":"2015","unstructured":"Hohmann N, Kocheise F, Carls A, Burhenne J, Haefeli WE, Mikus G. Midazolam microdose to determine systemic and pre-systemic metabolic CYP3A activity in humans. Br J Clin Pharmacol. 2015;79(2):278\u201385.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"416_CR18","first-page":"185","volume":"3","author":"M Gibaldi","year":"1974","unstructured":"Gibaldi M, Perrier D. Route of administration and drug disposition. Drug Metab Rev. 1974;3(2):185\u201399.","journal-title":"Drug Metab Rev"},{"issue":"1","key":"416_CR19","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2165\/00003088-200038010-00003","volume":"38","author":"GK Dresser","year":"2000","unstructured":"Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet. 2000;38(1):41\u201357.","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"416_CR20","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/cpt1976192135","volume":"19","author":"R Gugler","year":"1976","unstructured":"Gugler R, Manion CV, Azarnoff DL. Phenytoin: pharmacokinetics and bioavailability. Clin Pharmacol Ther. 1976;19(2):135\u201342.","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"416_CR21","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1111\/j.1365-2125.2009.03545.x","volume":"68","author":"DJ Greenblatt","year":"2009","unstructured":"Greenblatt DJ, Peters DE, Oleson LE, Harmatz JS, MacNab MW, Berkowitz N, et al. Inhibition of oral midazolam clearance by boosting doses of ritonavir, and by 4,4-dimethyl-benziso-(2H)-selenazine (ALT-2074), an experimental catalytic mimic of glutathione oxidase. Br J Clin Pharmacol. 2009;68(6):920\u20137.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"416_CR22","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1097\/MJT.0b013e318293b10a","volume":"22","author":"R Ciftci","year":"2015","unstructured":"Ciftci R, Tas F, Karabulut S, Ciftci S. Combination of capecitabine and phenytoin may cause phenytoin intoxication: a case report. Am J Ther. 2015;22(1):e17\u20139.","journal-title":"Am J Ther"},{"issue":"9","key":"416_CR23","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1248\/bpb.28.1805","volume":"28","author":"T Niwa","year":"2005","unstructured":"Niwa T, Shiraga T, Takagi A. Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomes. Biol Pharm Bull. 2005;28(9):1805\u20138.","journal-title":"Biol Pharm Bull"},{"issue":"8","key":"416_CR24","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1002\/jps.24064","volume":"103","author":"K Vanstraelen","year":"2014","unstructured":"Vanstraelen K, Wauters J, De Loor H, Vercammen I, Annaert P, Lagrou K, et al. Protein-binding characteristics of voriconazole determined by high-throughput equilibrium dialysis. J Pharm Sci. 2014;103(8):2565\u201370.","journal-title":"J Pharm Sci"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-016-0416-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40262-016-0416-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-016-0416-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-016-0416-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T15:41:14Z","timestamp":1559490074000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40262-016-0416-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,28]]},"references-count":24,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["416"],"URL":"https:\/\/doi.org\/10.1007\/s40262-016-0416-1","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,28]]}}}